Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFICACY AND TOXICITY OF 2-CHLORODEOXYADENOSINE (CLADRIBINE) - 2 H INFUSION FOR 5 DAYS - AS FIRST-LINE TREATMENT FOR ADVANCED LOW-GRADE NON-HODGKINS-LYMPHOMA
Autore:
FRIDRIK MA; JAGER G; KIENZER HR; HAUSMANINGER H; OPPITZ P; KRIEGER O; ZABERNIGG A; LANG A; NEUBAUER M; WEIDINGER G; SCHILLER L; SEEWANN HL; CHOTT A; LINKESCH W;
Indirizzi:
GEN HOSP LINZ,DEPT MED 1 LINZ AUSTRIA GRAZ UNIV,DEPT HAEMATOL A-8010 GRAZ AUSTRIA KAISER FRANZ JOSEF HOSP,DEPT MED 3 VIENNA AUSTRIA GEN HOSP,DEPT ONCOL SALZBURG AUSTRIA GEN HOSP,DEPT MED 3 WELS AUSTRIA ELISABETHINEN HOSP,DEPT MED 1 LINZ AUSTRIA GEN HOSP,DEPT MED FELDKIRCH AUSTRIA BH BRUDER HOSP,DEPT MED GRAZ AUSTRIA GEN HOSP WIENER NEUSTADT,DEPT MED 1 NEUSTADT GERMANY UNIV VIENNA,DEPT CLIN PATHOL VIENNA AUSTRIA
Titolo Testata:
European journal of cancer
fascicolo: 10, volume: 34, anno: 1998,
pagine: 1560 - 1564
SICI:
0959-8049(1998)34:10<1560:EATO2(>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
2-CDA THERAPY; FLUDARABINE; INFECTIONS;
Keywords:
LYMPHOMA; LOW GRADE; INTERMEDIATE GRADE; NON-HODGKINS; TREATMENT; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Fridrik et al., "EFFICACY AND TOXICITY OF 2-CHLORODEOXYADENOSINE (CLADRIBINE) - 2 H INFUSION FOR 5 DAYS - AS FIRST-LINE TREATMENT FOR ADVANCED LOW-GRADE NON-HODGKINS-LYMPHOMA", European journal of cancer, 34(10), 1998, pp. 1560-1564

Abstract

2-Chlorodeoxyadenosine (Cladribine) is a new purine analogue with high activity in pretreated low grade non-Hodgkin's lymphoma (NHL). To evaluate the efficacy of this drug in untreated patients with advanced NHL, we performed a prospective multicentre trial. Cladribine (0.12 mg/kg) was administered intravenously daily for 5 consecutive days in an out-patient setting. The treatment was repeated every 28 days for fourcycles. Included were patients with a histological diagnosis of low grade NHL according to the Kiel classification and stage III or IV disease. Stage II patients were included when radiotherapy had failed. 55 patients were entered into the study. 50 patients were evaluable. The remission rate was 44/50 (88%; 95% confidence interval 82-100%), including complete remissions (CR) in 14 (28%) patients. Only 2 patients showed progression while on Cladribine treatment. The estimated overall survival, and time to treatment failure (TTF) were 85% and 51%, respectively, after a median observation time of 92 weeks. 11 (22%) patientsshowed grade 3 or 4 toxicity according to the WHO grading. Haematological toxicity was responsible for 86% of the overall toxicity and 100%of grade 3 and 4 toxicity. 7 patients (14%) had an infection, two of which were opportunistic. 12 (24%) patients did not experience any toxicity during the treatment. The results of this study clearly demonstrate the safety and considerable activity of this regimen. Cladribine is very effective even at lower doses than have been used so far. (C) 1998 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 16:27:25